MOUNTAIN VIEW, Calif., March 27 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it has licensed its public-source Type II Diabetes meta- database to a Top 20 global pharmaceutical company. The customer expects to use the database to build quantitative models of the competitive landscape for oral diabetes treatments that will support clinical program decision-making for promising compounds in its diabetes pipeline. This is the second license Pharsight has sold for its diabetes meta-database.
Pharsight’s meta-database for Type II Non-Insulin Dependent Diabetes Mellitus (NIDDM) captures clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments and more than 30 clinical endpoints.
Pharsight has assembled a team of clinical database and clinical pharmacy experts dedicated to extracting information from the public domain and transforming this information into model-ready datasets. These datasets are used by biopharmaceutical companies and Pharsight scientific consultants to answer a variety of drug development questions. Pharsight offers public-source meta-databases in nine therapeutic areas, covering 20 disease indications. Additional information is available at http://www.pharsight.com/services/scs_sub_metadata.php.
“Pharsight is pleased that another leading pharmaceutical company has elected to use our meta-database to enable objective comparisons of drug effects for its diabetes programs,” said Shawn O’Connor, president, chief executive officer and chairman of Pharsight. “Using public domain data extracted from the scientific literature to build predictive models of the competitive landscape provides a quantitative means for understanding the clinical potential of a drug candidate and earlier assessment of its’ competitive viability. Pharsight systematically compiles public-source clinical databases, many in high-prevalence disease areas, with a deliberate focus to enable knowledge sharing and efficient drug-disease modeling to support our client’s critical drug development decisions.”
About Pharsight Public-Source Meta-databases
Pharsight meta-databases provide highly structured quantitative information from the public-source scientific literature that can be used to understand the competitive landscape for a particular therapeutic area and indication. Meta-databases provide a starting point for model-based drug development approaches, and when combined with proprietary data on specific compound(s) can be used to manage risk and address specific drug development program questions concerning dose selection, efficient and effective trial design, and “go/no-go” decisions. Pharsight offers meta-databases in nine therapeutic areas, covering 20 disease indications that include type II diabetes, thrombosis, depression and insomnia.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
The statements in this press release related to the design and performance of the Pharsight public-source meta-database offering are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight’s expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company’s most recent Form 10-Q filed with the Securities and Exchange Commission on February 14, 2008. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
CONTACT: Investors, Douglas Sherk or Matthew Selinger, or Media, Steve
DiMattia or Donald Takaya, all of EVC Group, +1-415-896-6820
Web site: http://www.pharsight.com/
http://www.pharsight.com/services/scs_sub_metadata.php/
